Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Aclaris Therapeutics (ACRS) Enterprise Value (2017 - 2025)

Aclaris Therapeutics (ACRS) has 9 years of Enterprise Value data on record, last reported at -$90.8 million in Q4 2025.

  • For Q4 2025, Enterprise Value rose 20.11% year-over-year to -$90.8 million; the TTM value through Dec 2025 reached -$90.8 million, up 20.11%, while the annual FY2025 figure was -$90.8 million, 20.11% up from the prior year.
  • Enterprise Value reached -$90.8 million in Q4 2025 per ACRS's latest filing, up from -$95.9 million in the prior quarter.
  • Across five years, Enterprise Value topped out at -$22.8 million in Q2 2024 and bottomed at -$248.6 million in Q2 2022.
  • Average Enterprise Value over 5 years is -$131.6 million, with a median of -$119.4 million recorded in 2023.
  • Peak YoY movement for Enterprise Value: soared 84.26% in 2023, then tumbled 337.09% in 2025.
  • A 5-year view of Enterprise Value shows it stood at -$191.4 million in 2021, then dropped by 13.67% to -$217.6 million in 2022, then surged by 45.26% to -$119.1 million in 2023, then grew by 4.63% to -$113.6 million in 2024, then increased by 20.11% to -$90.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Enterprise Value were -$90.8 million in Q4 2025, -$95.9 million in Q3 2025, and -$99.8 million in Q2 2025.